Article · Wikipedia archive · Last revised Jul 8, 2026

Olorofim

Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections. If approved it would be a first-in-class medication. In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug. Olorofim does not inhibit growth of Candida species.

Last revised
Jul 8, 2026
Read time
≈ 1 min
Length
144 w
Citations
4
Source
Wikipedia ↗
Olorofim
Clinical data
Other namesF901318
Legal status
Legal status
  • Investigational
Identifiers
  • 2-(1,5-Dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H27FN6O2
Molar mass498.562 g·mol−1

Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections.12 If approved it would be a first-in-class medication (for the orotomide class). In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug.3 Olorofim does not inhibit growth of Candida species.2

References

References

  1. Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.
  2. Wiederhold, Nathan P. (2020). "Review of the Novel Investigational Antifungal Olorofim". Journal of Fungi. 6 (3): 122. doi:10.3390/jof6030122. ISSN 2309-608X. PMC 7557671. PMID 32751765.
  3. "FDA Passes on Olorofim Despite Critical Need for Antifungals". Medscape.